Evidence map›Paper›PMID 35789143›Full record

ArticleCancer science2022

ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.

Kazuko Miyakawa, Naoya Miyashita, Masafumi Horie, Yasuhiro Terasaki, Hidenori Tanaka, Hirokazu Urushiyama, Kensuke Fukuda, Yugo Okabe, Takashi Ishii, Naomi Kuwahara and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The Current Roadmap of Lung Cancer Biology, Genomics and Racial Disparity.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Super-enhancer omics in stem cell.Molecular cancer · 2024
    Review
  10. Review
  11. Review
  12. Super-enhancers complexes zoom in transcription in cancer.Journal of experimental & clinical cancer research : CR · 2023
    Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Kazuko MiyakawaDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Naoya MiyashitaDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-2464-5167
Masafumi HorieDepartment of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Yasuhiro TerasakiDepartment of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.
Hidenori TanakaDepartment of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Hirokazu UrushiyamaDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kensuke FukudaDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0605-6681
Yugo OkabeDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takashi IshiiDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Naomi KuwaharaDepartment of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.
Hiroshi I SuzukiDivision of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takahide NagaseDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Akira SaitoDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0184-1376
The University of Tokyo · JPNippon Medical School · JPAichi Cancer Center · JPKanazawa University · JPThe University of Osaka · JPUniversity of Tokyo Health Sciences · JP

Funding

Japan Society for the Promotion of Science 16H02653Japan Society for the Promotion of Science 18K08170Japan Society for the Promotion of Science 21K16111Takeda Science Foundation medical research grant
6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor with dismal prognosis. Recently, molecular subtypes of SCLC have been defined by the expression status of ASCL1, NEUROD1, YAP1, and POU2F3 transcription regulators. ASCL1 is essential for neuroendocrine differentiation and is expressed in the majority of SCLC. Although previous studies investigated ASCL1 target genes in SCLC cells, ASCL1-mediated regulation of miRNAs and its relationship to molecular subtypes remain poorly explored. Here, we performed genome-wide profiling of chromatin modifications (H3K27me3, H3K4me3, and H3K27ac) by CUT&Tag assay and ASCL1 knockdown followed by RNA sequencing and miRNA array analyses in SCLC cells. ASCL1 could preferentially regulate genes associated with super-enhancers (SEs) defined by enrichment of H3K27ac marking. Moreover, ASCL1 positively regulated several SE-associated miRNAs, such as miR-7, miR-375, miR-200b-3p, and miR-429, leading to repression of their targets, whereas ASCL1 suppressed miR-455-3p, an abundant miRNA in other molecular subtypes. We further elucidated unique patterns of SE-associated miRNAs in different SCLC molecular subtypes, highlighting subtype-specific miRNA networks with functional relevance. Notably, we found apparent de-repression of common target genes of different miRNAs following ASCL1 knockdown, suggesting combinatorial action of multiple miRNAs underlying molecular heterogeneity of SCLC (e.g., co-targeting of YAP1 by miR-9 and miR-375). Our comprehensive analyses provide novel insights into SCLC pathogenesis and a clue to understanding subtype-dependent phenotypic differences.

Indexed as

Lung NeoplasmsMicroRNAsSmall Cell Lung CarcinomaBasic Helix-Loop-Helix ProteinsCell Line, TumorGene Expression Regulation, NeoplasticHumansASCL1 protein, humanBasic Helix-Loop-Helix ProteinsMicroRNAsMIRN455 microRNA, humanASCL1miR-375small cell lung cancersuper-enhancerYAP1

Identifiers

PMID35789143
PMCPMC9633298
OpenAlexW4283808109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.